AI Science Tracker
EN

Yangzhou University

3 discoveries from 2022 to 2026

Discoveries

XGBoost identifies pathological microvascular invasion risk in liver cancer

Source check: Source checked. Not independent scientific confirmation.

Finding: An XGBoost model combined tumor diameter and three preoperative blood measures in 1,106 liver-cancer patients from two hospitals. Against postoperative pathology, AUC was 0.845 in 130 internal test patients and 0.793 in 451 patients from the second hospital. This retrospective classification does not establish improved surgical choices, survival benefit or a causal role of inflammation.

Technology: XGBoost; recursive feature elimination

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Boosted decision trees learn preoperative clinical associations with pathology-confirmed microvascular invasion.
Test and result
Training-cohort feature selection with internal and separate-hospital validation against pathological microvascular invasion.
Limitation / still unknown
Prospective clinical utility and treatment benefit remain unestablished; model selection compares multiple algorithms across validation cohorts and applicability beyond resected HCC is uncertain.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13525009/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Primary relevant model Methods, Results and limitations; exact primary identity and current primary PubMed correction/retraction relationships checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Supervised spectral analysis distinguishes colorectal precancerous lesions in a 100-person serum study

Source check: Source checked. Not independent scientific confirmation.

Finding: A serum spectroscopy study analyzed 30 healthy controls,30 people with colorectal precancerous lesions and 40 with colorectal cancer. Supervised class-discrimination optimization after principal-component analysis distinguished these groups in five-fold cross-validation; the reported precancer-versus-other-groups AUC was 0.96. These are internal classification results from 100 participants, without an independent screening cohort or demonstrated clinical benefit. Spectral differences do not establish a molecular disease mechanism.

Technology: Optimal Class Discrimination and Compactness Optimization; support vector machine; k-nearest neighbors

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
After PCA preprocessing, supervised Optimal Class Discrimination and Compactness Optimization learned separation of diagnostic classes from labeled spectra. SVM and nearest-neighbor classifiers provided comparison models; PCA alone is not the enabling AI contribution.
Test and result
Five-fold cross-validation of spectra from 100 participants across three diagnostic groups; source reports precancer-versus-other-groups AUC 0.96. Multiple measurements per sample were averaged before analysis.
Limitation / still unknown
No external patient cohort, prospective screening validation or treatment-benefit study. Methods report averaging five spatial spectra per sample and five-fold cross-validation, but do not explicitly establish patient-grouped fold assignment or fold-local PCA and component selection; reported internal spectral classification is not established patient-level screening performance. Biochemical interpretations remain associations.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.1002/btm2.70019 · https://pmc.ncbi.nlm.nih.gov/articles/PMC12478330/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Exact primary article-front DOI/title/PMCID and date; full relevant model Methods, Results and limitations; fresh PubMed publication types and correction/retraction relationship metadata..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Non-Coding Transcriptome Provides Novel Insights into the Escherichia coli F17 Susceptibility of Sheep Lamb

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: RNA-seq plus random-forest/XGBoost feature selection identified ncRNA associations with E. coli F17 susceptibility in challenged lambs. The measured association is exploratory and does not show causal ncRNA function.

Technology: XGBoost; random-forest

Publication: Publication status unspecified in annotation · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Methods describe challenged cohort and resistant/sensitive subsets; Results report selected transcripts; no functional validation is claimed.
Limitation / still unknown
Affiliation was not available in the reviewed primary bibliographic metadata. Publication status could not be established from the reviewed primary bibliographic metadata.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.mdpi.com/2079-7737/11/3/348 · https://pubmed.ncbi.nlm.nih.gov/35336723/

The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.